VIRIDIAN THERAPEUTICS INC
NASDAQ: VRDN (Viridian Therapeutics, Inc.)
Kemas kini terakhir: 13 jam lalu22.00
0.07 (0.32%)
| Penutupan Terdahulu | 21.93 |
| Jumlah Dagangan | 5,381,490 |
| Harga / Jualan (P/S) | 29.87 |
| Harga / Buku (P/B) | 4.42 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -130,369.45% |
| EPS Cair (TTM) | -3.35 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.82% |
| Nisbah Semasa (MRQ) | 19.49 |
| Aliran Tunai Operasi (OCF TTM) | -279.75 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -171.41 M |
| Pulangan Atas Aset (ROA TTM) | -32.62% |
| Pulangan Atas Ekuiti (ROE TTM) | -51.95% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Viridian Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.33 |
|
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.16% |
| % Dimiliki oleh Institusi | 114.61% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bellevue Group Ag | 30 Jun 2026 | 6,731,909 |
| Paradigm Biocapital Advisors Lp | 30 Jun 2026 | 6,723,788 |
| Kynam Capital Management, Lp | 30 Jun 2026 | 6,453,877 |
| Fairmount Funds Management Llc | 30 Jun 2026 | 5,090,928 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |